Overview of Fumast

What is Fumast? (Ketotifen Fumarate)

Fumast is the trade designation for a single-ingredient antiallergic medication whose active substance is Ketotifen Fumarate. This compound is a synthetic derivative used for the sustained management and prevention of allergic manifestations.

Property	Description
Active ingredient	Ketotifen (as the fumaric acid salt)
Form	Ophthalmic solution (eye drops); Oral dosage forms
Pharmacological class	Non-competitive Histamine H1-receptor antagonist; Mast cell stabilizer
Common use	General relief of allergic symptoms (e.g., irritation, itching)
Origin	Synthetic benzocycloheptathiophene derivative

What Type of Medicine is Ketotifen Fumarate?

Ketotifen Fumarate is a synthetic antiallergic agent classified as a Histamine H1 Inhibitor. The medication is a single-ingredient compound, with its therapeutic action delivered through a dual mechanism. Primarily, it acts as a selective H1-receptor antagonist, blocking the receptor sites that histamine, a key allergic mediator, uses to trigger immediate symptoms.

The medication’s dual nature is completed by its role as a mast cell stabilizer, which works by inhibiting these immune cells from releasing inflammatory chemicals upon allergen exposure. This stabilizing property is intended for controlling inflammation, positioning the medication for prophylactic management in addition to symptomatic relief.

Composition, Forms, and General Purpose

The drug is offered as an ophthalmic solution for topical use and in various oral forms for systemic administration, catering to both localized and systemic allergic symptoms. The ophthalmic solution is a formulation used for providing targeted relief for ocular symptoms, such as the itching experienced during seasonal allergy flares. The oral forms are designed for systemic absorption.

The general purpose of Fumast is to intervene in the allergic cascade to provide sustained relief. By preventing the release of inflammatory mediators and blocking the actions of mediators already present, the medication serves to reduce the intensity and duration of allergic responses, such as irritation and inflammation. This approach is intended for the long-term control of allergic discomfort.

Regulatory References

NIH DailyMed drug label for Ketotifen Fumarate

What side effects are possible with Fumast?

The official safety profile for Fumast (Ketotifen Fumarate) is structured based on the route of administration, with adverse reactions formally classified by frequency and grouped into System-Organ Classes (SOC).

For the ophthalmic solution, common adverse reactions, defined as those reported at an incidence of 10% or higher in clinical trials, include Conjunctival Hyperaemia (eye redness), Headache, and Rhinitis. Other documented SOCs affected include Eye Disorders, with effects such as Eye Pruritus, Dry Eyes, and Photophobia.

The systemic (oral) form is commonly associated with effects related to Nervous System and Metabolism and Nutrition Disorders, including Drowsiness, Sedation, Dry Mouth, Dizziness, and Weight Gain. Drowsiness and other initial effects are typically reported to be more frequent at the initiation of therapy and often decrease within one to two weeks of continuous use.

Safety notes for special populations include a greater potential for CNS stimulation (e.g., irritability, excitation) in children receiving oral forms. The ophthalmic solution’s safety and effectiveness have not been established in patients below the age of three years. The ophthalmic form holds a Pregnancy Category C classification.

Documented rare but serious adverse reactions include Convulsions and signs of Hepatic Involvement. The medication is formally contraindicated in individuals with known Hypersensitivity to any component. A high-level safety note confirms that the oral form may potentiate the effects of CNS depressants, other antihistamines, and alcohol.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Fumast is based on systemic effects that may result from an overdose. The documented clinical manifestations are primarily associated with central nervous system (CNS) and cardiovascular disturbances.

System Affected	Documented Manifestations
CNS	Severe drowsiness, confusion, disorientation, hyperexcitability, convulsions, and reversible coma.
Cardiovascular	Tachycardia (fast, irregular heartbeat) and hypotension (low blood pressure).

Emergency Actions Required by Regulation

In the event of a suspected overdosage, regulatory guidance mandates that emergency medical help must be sought immediately. Contacting a Poison Control Center is required upon suspicion or occurrence of symptoms. Patients require surveillance for a minimum of six to eight hours following acute management.

For management, no specific antidote is known. Therefore, treatment is explicitly defined as symptomatic and supportive care. Official procedures listed include considering gastric lavage or administration of activated charcoal for recent ingestion. Overdose scenarios may require specific interventions, such as the use of benzodiazepines or short-acting barbiturates for managing excitation or convulsions, as described in the official labeling.

Population-Specific Consideration

Regulatory documents specifically note that convulsions and hyperexcitability are manifestations that are particularly observed in children following overdosage.

Therapeutic Uses of Fumast

What Fumast Treats: Main Uses and Benefits

Ketotifen Fumarate (Fumast) is commonly used to help with sustained relief and prophylactic management across domains where patients experience symptoms related to inflammatory or irritative states. It is considered relevant for easing symptoms related to systemic imbalance and localized allergic manifestations.

The medication is relevant for easing intense manifestations associated with Allergic Conjunctivitis (eye allergies), where it helps manage ocular itching, redness, and excessive tearing; Mild to Moderate Atopic Asthma, where it supports the long-term management of recurrent wheezing and difficulty breathing; and Chronic Systemic Allergic Disorders, including chronic urticaria (hives). A key patient benefit is that the medication assists with maintaining functional stability and supports improved comfort when symptoms begin to interfere with daily functioning. It is utilized for managing symptom clusters that may become intense or disruptive, helping to ease the overall symptom burden during symptomatic periods.

Quick Fact: Relief for Ocular Itching

The use of this medication may assist with temporary prevention of symptoms related to physical discomfort and supports improved comfort for patients dealing with seasonal or perennial eye allergies.

Regulatory References

Health Canada Product Monograph

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fumast — Official Regulatory Information

Contraindicated Populations

Eligibility Entity	Regulatory Status
Hypersensitivity	Contraindicated in persons with a known hypersensitivity to Ketotifen or any component of the product.
Epilepsy / Seizures	Contraindicated for the oral formulation in patients with established epilepsy or a history of seizures.

Age-Related Eligibility

Population	Regulatory Status
Children	The ophthalmic solution is approved for use in children 3 years of age and older.
Infants	Safety and effectiveness have not been established in pediatric patients below the age of 3 years.
Older Adults	Approved for use; no specific dosage adjustment is required for patients above 65 years.

Condition-Specific and Physiological Status

Condition / Status	Regulatory Status
Renal / Hepatic Impairment	No dosage adjustment is required for patients with either renal impairment or hepatic impairment (ophthalmic form).
Lactation / Breastfeeding	The ophthalmic solution can be used during lactation.
Pregnancy	Safety in human pregnancy has not been established; use should be considered with caution.

Eligibility-Related Restrictions

Soft contact lenses must be removed before applying the ophthalmic solution and may be reinserted after 10–15 minutes. The product is not indicated to treat eye irritation caused by contact lenses. Regulatory documents establish eligibility by first prohibiting use in specific high-risk groups and then defining minimum age and physiological constraints. The medicine is approved for the ophthalmic use in broad adult populations and children three years and older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Fumast (Ketotifen Fumarate) focuses on documented pharmacodynamic potentiation and specific administration constraints, rather than pharmacokinetic interactions via major enzyme systems, which are not explicitly documented in official prescribing information.

Additive Central Nervous System Effects

Co-administration with certain substance categories and medicines may result in additive central nervous system (CNS) depressant effects. Regulatory labeling states that the effects of sedatives, hypnotics, and other antihistamines are subject to potentiation. Furthermore, the consumption of alcohol may lead to enhanced CNS depression due to this additive effect. This potentiation is a key consideration defined in official documents.

Pharmacodynamic Interaction Risk

A specific drug-drug interaction is documented with oral antidiabetic agents. Regulatory sources note that co-administration has been observed, in rare instances, to result in a reversible fall in the thrombocyte count. Official documents recommend monitoring of thrombocyte counts when both medicines are used simultaneously.

Administration Constraint (Ophthalmic Solution)

For the topical ophthalmic solution, a mandatory timing separation rule is in place concerning soft contact lenses. Due to the preservative benzalkonium chloride, a period of 10 minutes must elapse between the application of the eye drops and the reinsertion of soft contact lenses. This is a crucial constraint listed in the prescribing information.

Mechanism of Action

Dual-Action on Allergic Signaling: Blocking and Reducing Mediator Release

Fumast modulates the allergic cascade through two distinct mechanisms. The immediate effect involves acting as a non-competitive antagonist of the Histamine H1 receptors, thereby blocking the binding of histamine to surrounding target tissues. The more sustained action involves reducing the excitability of mast cells and basophils. This is primarily achieved by inhibiting the calcium influx required for the activation and subsequent degranulation of these cells, a process that releases inflammatory mediators like histamine and leukotrienes.

Intracellular and Systemic Modulation

Fumast's sustained mechanism is further supported by a minor inhibitory effect on the Phosphodiesterase (PDE) enzyme. This action increases the concentration of intracellular cyclic AMP ( cAMP), which promotes a decrease in activity within the immune cell secretory pathways. Engagement of these mechanisms alters the responsiveness of end-effector tissues. The receptor blockade and mediator prevention reduce the effects of high mediator activity on blood vessels and airways, resulting in a decrease in capillary permeability and the antagonism of smooth muscle contraction in the bronchi.

Dosage and Administration Information

How to Use Fumast

Fumast (Ketotifen Fumarate) is administered through two routes: oral for systemic effect, and ophthalmic (eye drops) for topical application. Instructions provide distinct dosing schedules and administration contexts for each route.

Oral Administration (Systemic Use)

The standard adult oral dosing schedule is 1 mg taken twice daily (b.i.d.) with food. The dose may be increased to 2 mg b.i.d. for maintenance, which represents the maximum established dose. To mitigate the risk of initial drowsiness, treatment may begin with 0.5 mg or 1 mg taken only at night for the first few days.

For systemic prophylactic use, treatment is typically maintained continuously for a minimum of two to three months to realize the full effect.

Age Group	Dosing Instruction
Children over 3 years	Standard adult dose (1 mg b.i.d.) is used.
Children 6 months to 3 years	Dose is 0.05 mg/kg body weight twice daily (typically using the syrup form).
Older Adults	No dose adjustment is generally necessary.

Ophthalmic Administration (Topical Use)

The dose for the ophthalmic solution is one drop administered into the affected eye(s) twice daily, with doses spaced 8 to 12 hours apart. The solution is strictly intended for application to the eye and is not for injection or oral use.

When using the drops, contact lenses must be removed before installation, and instructions specify waiting a minimum of ten minutes before reinserting soft contact lenses. If other eye medications are administered, a minimum waiting period of 5 minutes between the application of drops is required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fumast

Evidence for Use in Allergic Conjunctivitis (Eye Allergies)

Research examined the ophthalmic formulation of Fumast has primarily involved randomized controlled trials (RCTs). These studies were designed to be double-masked, comparing the drug against an inactive substance (placebo). This approach was studied for short periods, often assessing responses immediately after exposure to an allergen.

Researchers examined a primary measurement of the change in the patient-reported outcomes describing perceived discomfort, specifically the intensity of eye itching. Researchers also monitored objective signs such as eye redness, tearing, and eyelid swelling. Studies conducted during periods of increased symptom activity in both adults and children (typically aged 3 years and older) contribute to the broader evidence landscape for this use.

Evidence for Chronic Management of Mild to Moderate Atopic Asthma

The evidence landscape includes randomized controlled trials, where the medication was observed in patients, often used in addition to other existing asthma regimens. These studies were studied for a potential role in patterns related to the chronic management of asthma, a condition characterized by fluctuating or episodic manifestations.

These studies explored outcomes related to systemic or functional imbalance, such as measures of episodic or acute changes. Researchers examined how the use of the medicine was associated with patterns in the frequency of asthma attacks (exacerbations). An additional measure was studied for changes in the patient's requirement for other concomitant asthma medications, like rescue inhalers. The populations were studied for in these trials include adults and children.

Areas of Uncertainty and Research Gaps

Studies were structured to evaluate the duration of observed patterns for sustained-use medicines. Overall, while some long-term data exist, the evidence for sustained patterns is not fully established across all indications, and there is limited information regarding the effect of continuous use over several years.

Furthermore, the evidence quality varies across studies, particularly for the systemic uses like urticaria, where findings were mixed and may be based on older literature. Comparative evidence is lacking in some areas to directly evaluate its use against every available standard treatment across all indications. Study results reflect the specific conditions under which they were conducted.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Fumast (FAQ)

Q: What is the main difference between Fumast and other medicines for the same condition?

Official classification documents describe Fumast as having a dual mechanism of action. It is characterized as a non-competitive Histamine H1-receptor antagonist, which blocks the effects of histamine, and also as a mast cell stabilizer, which helps prevent the release of inflammatory chemicals. This combination of effects is the primary distinction in its pharmacological classification compared to medicines that only target one of these pathways.

Q: How long does it typically take to start feeling the effects of Fumast?

For the full preventive effect (prophylactic use), regulatory documents advise that systemic treatment be maintained continuously for a minimum of two to three months. This duration is required to realize the medicine's full action. Separately, if initial side effects like drowsiness occur, official safety information indicates these effects are often reported to decrease within one to two weeks of continuous use.

Q: Can Fumast be used long-term?

The treatment for systemic prophylactic use is advised to be maintained continuously for at least two to three months. While official prescribing information supports use over this period, the research evidence for sustained patterns over much longer periods (several years) is not fully established across every listed indication.

Q: Is Fumast intended to be a cure or a long-term management treatment?

Fumast is officially described as an antiallergic agent for the sustained management and prevention of allergic manifestations. Its role is to help control symptoms over time (prophylactic management) rather than being described as a cure. This positioning supports its use in the chronic management of conditions like asthma and allergies.

Q: What happens if I suddenly stop taking Fumast?

Official instructions advise that systemic treatment should be maintained continuously for the full minimum prescribed duration. Stopping the medication may be associated with the return of the symptoms the medicine was used to manage. Regulatory advice emphasizes adherence to prescribed usage conditions.

Q: What if I take too much Fumast by mistake?

High exposures may be associated with documented rare but serious adverse reactions, including Convulsions and signs of Hepatic (liver) Involvement. Official guidance documents recommend consulting a healthcare professional when high exposures are suspected.

Q: Why do official documents mention certain lab tests for people taking Fumast?

Official documents recommend the monitoring of thrombocyte (platelet) counts when the oral form is used simultaneously with oral antidiabetic agents. This monitoring is noted because, in rare instances, co-administration has been associated with a reversible fall in the thrombocyte count.

Q: What is the expected duration of treatment with Fumast?

For systemic (body-wide) prophylactic use, the official advice is that treatment is maintained continuously for a minimum of two to three months. This length of time is considered necessary to achieve the drug’s full intended effect.

Q: What is the difference between Fumast and a placebo in clinical trials?

Clinical research studies compared the effects of Fumast against an inactive substance (placebo) by measuring specific outcomes. These outcomes included both patient reports, such as the intensity of eye itching, and objective signs, such as eye redness and swelling. The documented difference between the active drug and the placebo reflects the drug's effect in the context of the trial conditions.

Q: Do the side effects of Fumast get better over time?

Official safety information for the oral form notes that some common initial effects may lessen over time. For example, side effects like drowsiness or sedation are reported to be most frequent at the start of therapy but often decrease within one to two weeks of continuous use.

Q: I forgot a dose of Fumast, what should I do?

The advice in drug information sheets typically states that a missed dose may be taken as soon as it is remembered, unless it is close to the time for the next scheduled dose. If it is close to the next dose, the instruction is often to skip the missed one. This approach is intended to avoid administering two doses closely together.

Q: Do I need to take Fumast with food?

The official instructions for the standard adult oral dosing schedule state that the medicine is to be taken twice daily with food. This condition is specified in the prescribing information for the oral form.

Q: Is Fumast approved in countries outside of the US?

Regulatory documentation confirms that Fumast is approved and marketed across many international regions. The ophthalmic form is marketed globally, and the oral form holds approval in countries including Japan, Canada, and various European countries.

Q: Is Fumast available as a generic medicine?

The active substance in Fumast, Ketotifen Fumarate, is available as a generic ingredient in multiple formulations. Regulatory patent filings and market data indicate that many of the formulations are considered off-patent.

Q: Why do people say they feel 'spacey' or 'foggy' when they take this medicine?

The feelings described as 'spacey' or 'foggy' are likely related to the central nervous system (CNS) effects documented in the official safety profile. Common adverse reactions for the oral form include Drowsiness, Sedation, and Dizziness. These are recognized effects linked to the medicine's activity in the CNS.

Q: Is Fumast safe to use during pregnancy or while breastfeeding?

The official regulatory information addresses use during pregnancy and breastfeeding. For pregnancy, the safety in humans has not been established, and use should be considered with caution. For breastfeeding, the ophthalmic solution can be used during lactation.

Q: Does the efficacy of Fumast change over time?

Research has studied the duration of effects for sustained-use medicines, including Fumast. While long-term use is common in practice, the available evidence regarding sustained effects over several years is not fully established across all indications listed in regulatory documents.

Q: Is Fumast related to a class of medicines called DMARDs?

No, Fumast is formally classified as a Histamine H1-receptor antagonist and a Mast cell stabilizer. It belongs to the antihistamine pharmacological class (ATC code R06AX17). DMARDs (Disease-Modifying Antirheumatic Drugs) are a separate category of medicines and are not the official classification for Fumast.

How should Fumast be stored and disposed of?

How to Store and Dispose of Fumast? (Ketotifen Fumarate)

Official regulatory guidelines define specific conditions for storing and discarding Ketotifen Fumarate (Fumast) to ensure product stability and safety.

Storage Requirement	Official Condition
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Container Rule	Keep the bottle tightly closed; do not touch the tip to any surface.
Stability Limit	Discard the solution four weeks after opening the bottle. Do not use if the liquid changes color or becomes cloudy.
Safety	The medication must be kept out of the reach of children.

For disposal, official instructions mandate that unused or expired product should not be emptied into drains or sewage systems. Patients should utilize a formal drug take-back program or consult a healthcare professional for guidance on safe disposal in accordance with local environmental regulations.

Fumast